New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma

RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma

August 31, 2023Kyle DohertyMitesh J. Borad, MD, highlights key additional findings from ReFocus and how RLY-4008 differs from currently available FGFR2 inhibitors.Mitesh J. Borad, MDThe first highly s
World medicine November 23,2023
RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma

RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma

August 31, 2023Kyle DohertyMitesh J. Borad, MD, highlights key additional findings from ReFocus and how RLY-4008 differs from currently available FGFR2 inhibitors.Mitesh J. Borad, MDThe first highly s
World medicine November 23,2023
Testing hundreds of existing therapeutics to fight blood cancer more effectively

Testing hundreds of existing therapeutics to fight blood cancer more effectively

Multiple myeloma is a rare blood cancer caused by the uncontrolled multiplication of abnormal plasma cells. These plasma cells are a special type of white blood cells that play an important role in th
World medicine November 23,2023
Testing hundreds of existing therapeutics to fight blood cancer more effectively

Testing hundreds of existing therapeutics to fight blood cancer more effectively

Multiple myeloma is a rare blood cancer caused by the uncontrolled multiplication of abnormal plasma cells. These plasma cells are a special type of white blood cells that play an important role in th
World medicine November 23,2023
REGAL Trial Examining Galinpepimut-S in AML to Continue Without Modifications

REGAL Trial Examining Galinpepimut-S in AML to Continue Without Modifications

August 24, 2023Kristi RosaAn independent data monitoring committee has recommended that the phase 3 REGAL trial evaluating galinpepimut-S in patients with acute myeloid leukemia should continue withou
World medicine November 23,2023
REGAL Trial Examining Galinpepimut-S in AML to Continue Without Modifications

REGAL Trial Examining Galinpepimut-S in AML to Continue Without Modifications

August 24, 2023Kristi RosaAn independent data monitoring committee has recommended that the phase 3 REGAL trial evaluating galinpepimut-S in patients with acute myeloid leukemia should continue withou
World medicine November 23,2023
PROSPECT Trial Confirms Feasibility of De-escalation of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

PROSPECT Trial Confirms Feasibility of De-escalation of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

August 23, 2023Courtney FlahertyMichael Cecchini, MD, expands on key updates in gastrointestinal cancer from the 2023 ASCO Annual Meeting, including the clinical significance of findings from the PROS
World medicine November 23,2023
PROSPECT Trial Confirms Feasibility of De-escalation of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

PROSPECT Trial Confirms Feasibility of De-escalation of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer

August 23, 2023Courtney FlahertyMichael Cecchini, MD, expands on key updates in gastrointestinal cancer from the 2023 ASCO Annual Meeting, including the clinical significance of findings from the PROS
World medicine November 23,2023
NVL-655 Elicits Preliminary Activity, Safety in Heavily Pretreated, ALK+ Advanced NSCLC

NVL-655 Elicits Preliminary Activity, Safety in Heavily Pretreated, ALK+ Advanced NSCLC

October 13, 2023Ryan ScottTreatment with the novel, ALK-selective TKI NVL-655 generated responses and was well tolerated in heavily pretreated patients with ALK-positive, advanced non–small cell lung
World medicine November 23,2023
NVL-655 Elicits Preliminary Activity, Safety in Heavily Pretreated, ALK+ Advanced NSCLC

NVL-655 Elicits Preliminary Activity, Safety in Heavily Pretreated, ALK+ Advanced NSCLC

October 13, 2023Ryan ScottTreatment with the novel, ALK-selective TKI NVL-655 generated responses and was well tolerated in heavily pretreated patients with ALK-positive, advanced non–small cell lung
World medicine November 23,2023
Using engineered stem cells to treat ALS and retinitis pigmentosa

Using engineered stem cells to treat ALS and retinitis pigmentosa

Cedars-Sinai investigators are developing a novel way to treat amyotrophic lateral sclerosis (ALS) and retinitis pigmentosa using engineered stem cells that may eventually lead to personalized treatme
World medicine November 23,2023
Using engineered stem cells to treat ALS and retinitis pigmentosa

Using engineered stem cells to treat ALS and retinitis pigmentosa

Cedars-Sinai investigators are developing a novel way to treat amyotrophic lateral sclerosis (ALS) and retinitis pigmentosa using engineered stem cells that may eventually lead to personalized treatme
World medicine November 23,2023
NCCN Endorses Goserelin in Salivary Gland Tumors in New Head and Neck Cancers Guidelines

NCCN Endorses Goserelin in Salivary Gland Tumors in New Head and Neck Cancers Guidelines

November 13, 2023Kyle DohertyTerSera Therapeutics LLC announced that The National Comprehensive Cancer Network Head and Neck Cancers Panel recommended the GnRH agonist goserelin for patients with recu
World medicine November 23,2023
NCCN Endorses Goserelin in Salivary Gland Tumors in New Head and Neck Cancers Guidelines

NCCN Endorses Goserelin in Salivary Gland Tumors in New Head and Neck Cancers Guidelines

November 13, 2023Kyle DohertyTerSera Therapeutics LLC announced that The National Comprehensive Cancer Network Head and Neck Cancers Panel recommended the GnRH agonist goserelin for patients with recu
World medicine November 23,2023
Maintenance Mirvetuximab Soravtansine Plus Bevacizumab Under Exploration in FRα+ Ovarian Cancer

Maintenance Mirvetuximab Soravtansine Plus Bevacizumab Under Exploration in FRα+ Ovarian Cancer

September 1, 2023Courtney FlahertyThe efficacy of maintenance mirvetuximab soravtansine plus bevacizumab is being compared with bevacizumab alone in patients with folate receptor alpha–positive recurr
World medicine November 23,2023
Maintenance Mirvetuximab Soravtansine Plus Bevacizumab Under Exploration in FRα+ Ovarian Cancer

Maintenance Mirvetuximab Soravtansine Plus Bevacizumab Under Exploration in FRα+ Ovarian Cancer

September 1, 2023Courtney FlahertyThe efficacy of maintenance mirvetuximab soravtansine plus bevacizumab is being compared with bevacizumab alone in patients with folate receptor alpha–positive recurr
World medicine November 23,2023
FDA Grants Fast Track Designation to DOC1021 for Glioblastoma

FDA Grants Fast Track Designation to DOC1021 for Glioblastoma

October 17, 2023Ashling WahnerThe FDA has granted a fast track designation to the dendritic cell vaccine DOC1021 for use as a potential therapeutic option in patients with glioblastoma multiforme.FDAT
World medicine November 23,2023
FDA Grants Fast Track Designation to DOC1021 for Glioblastoma

FDA Grants Fast Track Designation to DOC1021 for Glioblastoma

October 17, 2023Ashling WahnerThe FDA has granted a fast track designation to the dendritic cell vaccine DOC1021 for use as a potential therapeutic option in patients with glioblastoma multiforme.FDAT
World medicine November 23,2023
FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS

FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS

August 28, 2023Kristi RosaThe FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia without prior erythropoiesis-stimulating agent (ESA) use in adult patients with very low– to int
World medicine November 23,2023
FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS

FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS

August 28, 2023Kristi RosaThe FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia without prior erythropoiesis-stimulating agent (ESA) use in adult patients with very low– to int
World medicine November 23,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com